Tigris Pharmaceuticals Inc.

Tigris Pharmaceuticals Inc. is focused on the development and provision of specialized pharmaceutical products that aim to address complex healthcare needs through innovative solutions. Founded in 2005 in Bonita Springs, US, Tigris Pharmaceuticals Inc. develops pharmaceutical products for various medical conditions.

The company has completed two significant deals, with the latest being a Series C financing round in October 2010, securing USD 6. 5 mn from Bushido Capital Partners, Sonostar Ventures, and Wexford Capital. The current CEO is the TIGRI Team. Tigris Pharmaceuticals specializes in pharmaceutical products tailored to meet the needs of healthcare providers and patients.

Their offerings include a range of prescription medications aimed at improving treatment outcomes, serving hospitals, clinics, and healthcare practitioners across North America and selected international markets. The revenue model of Tigris Pharmaceuticals is based on direct sales to healthcare institutions, utilizing a B2B transactional structure. Clients engage with the company under established pricing agreements for pharmaceutical products, with revenue generation supported by long-term relationships with healthcare providers, ensuring consistent demand for their offerings. Tigris Pharmaceuticals plans to utilize the USD 6.

5 mn raised in the Series C financing round to support the development of new pharmaceutical products and expand market reach. The company aims to introduce innovative solutions that meet unmet medical needs and seeks to penetrate additional international markets by 2015. Overall, the recent funding will bolster their capacity to enhance product offerings and improve healthcare outcomes.